Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference
Date:9/20/2010

NEW YORK and JERUSALEM, Sept. 21 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Wednesday, September 22, 2010 at 11:00 AM (ET).

Chiasma is currently conducting its second clinical trial of the investigational new drug Octreolin™, an oral form of octreotide acetate that uses the proprietary Transient Permeability Enhancer (TPE) system for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  A third clinical trial is planned to start by the end of 2010. The Food and Drug Administration has granted orphan drug designation for Octreolin and the Company will submit an application for Orphan Medicinal Product Designation to the European Medicines Agency (EMA) shortly.

Upon receipt of positive Phase 3 efficacy and safety data, the Company will submit an NDA using the "505(b)(2) regulatory pathway" in the United States and its equivalent, the "Hybrid Application," in Europe.

Chiasma is also developing Octreolin as a potential treatment for patients with portal hypertension (PHT); there are currently no drugs approved for PHT in the U.S.

About Chiasma

Chiasma is evaluating the TPE technology with approved drugs, which may enable their being switched from injectable to oral, and potentially may also result in new indications or otherwise improved labels.  The TPE technology promotes the delivery of drugs to the GI wall and from there to the liver.  It is applicable to macromolecules that, to date, can be administered only by injection.  TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.  The Company has successfully demonstrated proof-of-principle in delivering small proteins, peptides, saccharides and heretofore-insoluble small molecules via the oral route.

The Company is backed by ARCH Venture Partners, MPM Capital, F2 Ventures, 7 Health Ventures and the MPM Novartis Strategic Fund. Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary. Additional information can be found at:  www.ChiasmaPharma.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.  Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events o otherwise.


'/>"/>
SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly
2. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
3. Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
4. Caliper Life Sciences CEO to Present Keynote Presentation at MipTec European Conference
5. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
6. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
7. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
8. CryoLife to Present at UBS Global Life Sciences Conference
9. Sigma-Aldrich to Present at the UBS Global Life Sciences Healthcare Conference on Tuesday, September 21, 2010
10. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
11. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):